User login
Key clinical point: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator use was associated with reduced incidence of acute pancreatitis (AP) hospitalizations in pancreas-sufficient (PS) and pancreas-insufficient (PI) patients with CF.
Major finding: Estimated rates of AP hospitalizations per 1000 patient-years in patients with PS-CF and PI-CF treated with CFTR modulator were 3.26 (95% CI 0.94-11.33) and 0.66 (95% CI 0.26-1.68), respectively, and those not treated with CFTR modulator were 10.20 (95% CI 6.19-16.81) and 1.76 (95% CI 0.98-3.17), respectively.
Study details: Findings are from a retrospective analysis of 10,417 patients with CF (PS n = 3,759; PI n = 6,658) with (17.2%) or without previous CFTR modulator use.
Disclosures: This study was supported by the US National Center for Advancing Translational Sciences. The authors declared no conflict of interests.
Source: Ramsey ML et al. Am J Gastroenterol. 2021(Oct 19). Doi: 10.14309/ajg.0000000000001527.
Key clinical point: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator use was associated with reduced incidence of acute pancreatitis (AP) hospitalizations in pancreas-sufficient (PS) and pancreas-insufficient (PI) patients with CF.
Major finding: Estimated rates of AP hospitalizations per 1000 patient-years in patients with PS-CF and PI-CF treated with CFTR modulator were 3.26 (95% CI 0.94-11.33) and 0.66 (95% CI 0.26-1.68), respectively, and those not treated with CFTR modulator were 10.20 (95% CI 6.19-16.81) and 1.76 (95% CI 0.98-3.17), respectively.
Study details: Findings are from a retrospective analysis of 10,417 patients with CF (PS n = 3,759; PI n = 6,658) with (17.2%) or without previous CFTR modulator use.
Disclosures: This study was supported by the US National Center for Advancing Translational Sciences. The authors declared no conflict of interests.
Source: Ramsey ML et al. Am J Gastroenterol. 2021(Oct 19). Doi: 10.14309/ajg.0000000000001527.
Key clinical point: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulator use was associated with reduced incidence of acute pancreatitis (AP) hospitalizations in pancreas-sufficient (PS) and pancreas-insufficient (PI) patients with CF.
Major finding: Estimated rates of AP hospitalizations per 1000 patient-years in patients with PS-CF and PI-CF treated with CFTR modulator were 3.26 (95% CI 0.94-11.33) and 0.66 (95% CI 0.26-1.68), respectively, and those not treated with CFTR modulator were 10.20 (95% CI 6.19-16.81) and 1.76 (95% CI 0.98-3.17), respectively.
Study details: Findings are from a retrospective analysis of 10,417 patients with CF (PS n = 3,759; PI n = 6,658) with (17.2%) or without previous CFTR modulator use.
Disclosures: This study was supported by the US National Center for Advancing Translational Sciences. The authors declared no conflict of interests.
Source: Ramsey ML et al. Am J Gastroenterol. 2021(Oct 19). Doi: 10.14309/ajg.0000000000001527.